Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -161.55% is 149% below its 5-year average of -64.88%, near the low end of its 5-year range (-161.55%–-27.13%).
137.22% below its 12-month average of -68.10%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -46.15%.
RETURN ON ASSETS (ROA)
-161.55%
RETURN ON ASSETS (ROA) AVG TTM
-68.10%
RETURN ON ASSETS (ROA) AVG 3Y
-58.95%
RETURN ON ASSETS (ROA) AVG 5Y
-64.88%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-137.22%
CURRENT VS 3Y AVG
-174.07%
CURRENT VS 5Y AVG
-149.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-401.09%
vs the sector median at left
Pyxis Oncology, Inc.
Market Cap
$127.98M
Return on Assets (ROA)
-161.55%
TTM Avg
-68.10%
3Y Avg
-58.95%
5Y Avg
-64.88%
Market Cap
$127.29M
Return on Assets (ROA)
-68.74%
TTM Avg
-454.56%
3Y Avg
-368.82%
5Y Avg
-586.69%
Market Cap
$130.79M
Return on Assets (ROA)
-73.85%
TTM Avg
-21.75%
3Y Avg
-19.65%
5Y Avg
-19.48%
Market Cap
$131.21M
Return on Assets (ROA)
-6.07%
TTM Avg
-5.08%
3Y Avg
-4.92%
5Y Avg
-1.70%
Market Cap
$124.70M
Return on Assets (ROA)
-87.44%
TTM Avg
-86.57%
3Y Avg
-87.06%
5Y Avg
-85.09%
Market Cap
$124.18M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$132.03M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$122.66M
Return on Assets (ROA)
-62.84%
TTM Avg
-62.29%
3Y Avg
-62.24%
5Y Avg
-56.44%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | $127.98M | -161.55% | -68.10% | -58.95% | -64.88% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | -68.74% | -454.56% | -368.82% | -586.69% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | -73.85% | -21.75% | -19.65% | -19.48% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | -6.07% | -5.08% | -4.92% | -1.70% |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | -87.44% | -86.57% | -87.06% | -85.09% |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | -96.49% | -109.25% | -126.41% | -190.40% |
| LifeMD, Inc. (LFMD)vs › | $132.03M | -35.50% | -18.07% | -62.20% | -134.72% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -62.84% | -62.29% | -62.24% | -56.44% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | -4.60% | -3.66% | -5.21% | -1.02% |
ROA
-161.6%
ROE
-775.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -87.00% |
| 2024-12-31 | -49.20% |
| 2023-12-31 | -42.47% |
| 2022-12-31 | -57.11% |
| 2021-12-31 | -27.13% |
| 2020-12-31 | -126.37% |
| 2019-12-31 | -14.00% |
